

COVID-19 Vaccine Update

Webinar 3

Date: November 29th, 2022

Presentation By:

Allie Staton, PharmD

Vaccine Confidence Strategist

Immunize Arkansas

Email: allie@immunizear.org



UAMS DISCLOSURE POLICY

It is the policy of the University of Arkansas for Medical Sciences (UAMS) to ensure balance, independence, objectivity, and scientific rigor in all directly or jointly provided educational activities.

All individuals who are in a position to control the content of the educational activity (course/activity directors, planning committee members, staff, teachers, or authors of CE) must disclose all relevant financial relationships they have with any commercial interest(s) as well as the nature of the relationship. The ACCME and ACPE describe relevant financial relationships as those in any amount occurring within the past 24 months that create a conflict of interest. *Individuals who refuse to disclose will be disqualified from participation in the development, management, presentation, or evaluation of the CE activity.*

DISCLOSURES

The following planners and speakers of this CE activity have no relevant financial relationships with ineligible companies to disclose:

Allie Staton, PharmD

The accreditation compliance reviewers, Courtney Bryant and Sara Hale, have no relevant financial relationships with ineligible companies to disclose.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



CREDIT DESIGNATION STATEMENTS

AMA Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit Designation Statement

These knowledge based activities will provide pharmacists up to 1.0 contact hours or 0.1 CEU. CE credit information, based on verification of live attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion.

ANCC Credit Designation Statement

The University of Arkansas for Medical Sciences designates this live activity for a maximum of 1.0 ANCC contact hours. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials.

AAPA Credit Designation Statement

The University of Arkansas for Medical Sciences has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

CONTINUING EDUCATION

To receive Continuing Education:

- **You must attend this webinar as it is being presented.**
 - Attendance will be recorded via Zoom to determine if you were present.
 - If you are watching this as a recording, you will not be eligible to receive CE.
- **You must complete the Evaluation Survey following this webinar.**
 - A link to the Evaluation Survey will be posted in the chat at the end of the presentation.
 - **DEADLINE: Midnight on Wednesday, November 30th**
 - **No late evaluations will be accepted.** Please complete the survey ASAP.
 - The survey link will also be sent out tomorrow in a follow-up email.
- **Certificates of Completion for attending this course will be available after you complete the Evaluation Survey.**
 - There will be a link provided at the end of the Evaluation Survey to access the Certificates of Completion.
 - You will have to write your name on the Certificate.
 - A link to the Certificates of Completion will also be sent out tomorrow in a follow-up email.

WEBINAR

- If you have a question during the webinar, please post your question in the chat.
 - We will do our best to answer all questions before the end of the webinar.
- If you have a question after the webinar, please email Allie Staton.
 - allie@immunizear.org

OBJECTIVES

At the end of this webinar, learners will be able to:

- Interpret current COVID-19 vaccine guidelines.
- Recommend appropriate vaccines to patients and community members.
- Discuss current COVID-19 vaccine guidelines and recommendations.


TOPICS

- Discussing COVID-19 vaccines with patients
- Review current COVID-19 vaccine booster recommendations
- Discuss commonly asked questions

DISCUSSING COVID-19 VACCINES

VACCINE HESITANCY

Core concepts: A continuum of attitudes and behaviours



Vaccine hesitancy: a delay in acceptance or refusal of vaccines, despite available services. Is complex and context specific, varying across time, place, and vaccine

VACCINE HESITANCY

Why are people hesitant to receive vaccines?

Distrust in the healthcare system	Not receiving a strong recommendation from a healthcare provider
Historical issues with vaccines	Vaccines not necessary
Misinformation	Concerned about side effects
Cost	Religious beliefs

ADDRESSING HESITANCY

Understand your audience

Create tailored messages

Motivational Interviewing

UNDERSTAND YOUR AUDIENCE

- What would motivate your audience to get vaccinated?
- How does your audience feel about getting vaccinated?
- Have others in their circle of influence had positive or negative experiences?
- What core beliefs, values, and moral foundations drive your intended audience's decision making?
- What is their literacy level for written communication and health information?
- Who do they trust for health information?
- What is their socio-cultural context? Don't make assumptions

CREATE TAILORED MESSAGES

- Incorporate values that resonate with your audience
- Invite people to have a conversation with their healthcare provider
 - It may help people to learn about vaccination from someone they know and trust
- Provide details about how to get vaccinated based on their learning style

MOTIVATIONAL INTERVIEWING

What is Motivational Interviewing?

Motivational Interviewing (MI) is a collaborative conversation to strengthen a person's own motivation for and commitment to change.

When using MI, your job is to help the patient identify *their own* values and *their own* motivation for change.



Builds a sense of trust between a patient and the provider



Allows patients to understand that we are not forcing our opinions/views on them



Introduces opportunities to provide non-biased educational information to patients



The patients have the resources they need and the opportunity to come to their own conclusions about what is best for them

**How does
motivational
interviewing help
us with vaccine
hesitancy?**

MOTIVATIONAL INTERVIEWING

Core Principles

Express Empathy	<ul style="list-style-type: none">• Empathy is the ability to understand and share the feelings of another.• Express empathy by not being judgmental and try to understand why a person has a certain opinion or certain questions.
Develop Discrepancy	<ul style="list-style-type: none">• There is discrepancy someone's actions are not in line with their values.• “Develop discrepancy” between what the patient says they want and what they are actually doing.<ul style="list-style-type: none">• Example: A patient wants to avoid getting COVID-19, but they do not want to take measures to prevent getting COVID-19. By not taking measures to prevent COVID-19, they are not taking actions that are in line with their value of not getting sick with COVID-19.
Roll with Resistance	<ul style="list-style-type: none">• Humans have a natural instinct to avoid being persuaded.• When a patient is resistant to making a change, act as a guide to help them understand their own resistance to change.
Support Self-Efficacy	<ul style="list-style-type: none">• Be encouraging and acknowledge when a patient has made an effort towards change.

MI: WHEN TO USE

- This intervention helps people become motivated to change the behaviors that are preventing them from making healthier choices.
- Research has shown that this intervention works well with individuals who start off unmotivated or unprepared for change.
- Motivational interviewing is also appropriate for people who are angry or hostile.
- They may not be ready to commit to change, but motivational interviewing can help them move through the emotional stages of change necessary to find their motivation.

MI: HOW TO USE

- In a supportive manner, a motivational interviewer encourages patients to talk about their need for change and their own reasons for wanting to change.
- The role of the interviewer is mainly to evoke a conversation about change and commitment.
- The interviewer listens and reflects back the patient's thoughts so that the patient can hear their reasons and motivations expressed back to them.

MOTIVATIONAL INTERVIEWING

If your patient is hesitant about getting a vaccine, use Motivational Interviewing techniques to discuss the vaccine with them.

Remember OARS:

- **Open-Ended Questions**
 - “What are some concerns you have about the vaccine?”
- **Affirmation**
 - “That is certainly a valid concern.”
- **Reflective Listening**
 - “So it sounds like...”
- **Summary**
 - “I’d like to make sure I haven’t missed anything...”

MOTIVATIONAL INTERVIEWING

OARS

<u>Open-Ended Questions</u>	These questions invite others to “tell their story” in their own words, without leading them in a specific direction.
<u>Affirmation</u>	Affirmations are statements and gestures that recognize the patient’s strengths and acknowledge behaviors that lead in the direction of a positive change.
<u>Reflective Listening</u>	Reflective listening is a pathway for engaging others in relationships, building trust, and fostering motivation to change.
<u>Summary</u>	Summarizing helps ensure that there is clear communication between the speaker and listener. It can also provide a stepping stone towards change.

WHAT NOT TO DO

- Don't "give up" on your COVID-19 vaccine recommendation if you are asked a question.
- Don't make up an answer to a question if you don't know the answer.
 - Be honest. It's okay to say you don't know the answer!
 - Tell them you'd be happy to research their question and get back with them.
- Don't assume people are up-to-date on their COVID-19 vaccines.
- Don't assume your patient knows anything about COVID-19 vaccines.

HELPFUL RESOURCES

Articles on Motivational Interviewing

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486954/>

<https://www.jabfm.org/content/35/2/420>

<https://news.unm.edu/news/researchers-urge-health-care-practitioners-to-use-motivational-interviewing-to-help-resolve-covid-19-vaccine>

CURRENT RECOMMENDATIONS

CDC INTERIM CLINICAL CONSIDERATIONS FOR COVID-19 VACCINES

COVID-19 vaccine recommendations are based on:

- Age
- Health Status
 - Healthy versus Moderately to Severely Immunocompromised
- Previous doses of COVID-19 vaccines

Recommendations for use of COVID-19 vaccines are published on the CDC's website.

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

COVID-19 Vaccine Recommendations

Booster Doses

Date: October 12th, 2022



Everyone ages 5 years and older is recommended to receive ONE age-appropriate bivalent mRNA booster dose at least 2 months after completion of any FDA-approved or FDA-authorized monovalent primary series or last monovalent booster dose.

- People cannot receive a bivalent booster dose without first completing a primary series of a monovalent vaccine product.
- Age-appropriate homologous and heterologous boosters are allowed; there is no preference.
 - **Pfizer bivalent boosters → authorized for ages 5 years and older**
 - 5 years – 11 years: Pfizer Orange Cap Bivalent Booster (0.2 mL) – *different product than for 12 and older*
 - 12 years and older: Pfizer Gray Cap Bivalent Booster (0.3 mL)
 - **Moderna bivalent booster → authorized for ages 6 years and older**
 - 6 years – 11 years: Moderna Bivalent Booster (0.25 mL) – *same product for 12 and older, but half the dose*
 - 12 years and older: Moderna Bivalent Booster (0.5 mL)

Vaccination History	→	Next dose
Primary series	At least 2 months →	1 bivalent booster dose
Primary series + 1 booster	At least 2 months →	1 bivalent booster dose
Primary series + 2 boosters	At least 2 months →	1 bivalent booster dose

Bivalent Booster Products	Age	Dose
Pfizer Bivalent (orange cap)	5 – 11 years	0.2 mL
Pfizer Bivalent (gray cap)	12 years and older	0.3 mL
Moderna Bivalent (blue cap, gray label)	6 – 11 years	0.25 mL
	12 years and older	0.5 mL

- The new bivalent booster recommendations **replace** previous booster recommendations for people ages 5 years and older.
 - Fall Booster “Reset” → moving forward, recommendations will be simplified.
 - Change from “dose counting” (ex. dose 4, dose 5, etc.) to ONE bivalent booster for everyone eligible.
- Monovalent vaccine products must still be used for **primary series** doses.
- Monovalent vaccine products are **no longer authorized for use as booster doses** for patients 5 years and older.
- Recommendations for COVID-19 vaccines for ages 6 months through 4 years have not changed.

COVID-19 Vaccine Recommendations

Healthy Adults: Administration of Primary Series and Booster Doses (ages 18 and older)

Date: October 12, 2022



PRIMARY SERIES (monovalent products only)				BOOSTER DOSES (bivalent products only)	
	Dose 1		Dose 2	Booster	
Pfizer Cap: Gray or Purple	(primary) Pfizer Monovalent: 0.3 mL	Wait 3 – 8 weeks →	(primary) Pfizer Monovalent: 0.3 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	(primary) Moderna Monovalent: 0.5 mL	Wait 4 – 8 weeks →	(primary) Moderna Monovalent: 0.5 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
Novavax	(primary) Novavax Monovalent: 0.5 mL	Wait 3 – 8 weeks →	(primary) Novavax Monovalent: 0.5 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	(primary) J&J Monovalent: 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
J & J J&J should only be used in limited situations					

See Child and Adolescent charts for recommendations for those under 18 years of age

Please see CDC Interim Clinical Considerations for official guidance.

COVID-19 Vaccine Recommendations

Immunocompromised Adults: Administration of Primary Series and Booster Doses (ages 18 and older)

Date: October 12, 2022



PRIMARY SERIES (monovalent products only)						BOOSTER DOSES (bivalent products only)	
	Dose 1		Dose 2		Dose 3	Booster	
Pfizer Cap: Gray or Purple	(primary) Pfizer Monovalent: 0.3 mL	Wait 3 weeks →	(primary) Pfizer Monovalent: 0.3 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> Pfizer Monovalent: 0.3 mL OR Moderna Monovalent: 0.5 mL	Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	(primary) Moderna Monovalent: 0.5 mL	Wait 4 weeks →	(primary) Moderna Monovalent: 0.5 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> Pfizer Monovalent: 0.3 mL OR Moderna Monovalent: 0.5 mL		
Novavax	(primary) Novavax Monovalent: 0.5 mL	Wait 3 weeks →	(primary) Novavax Monovalent: 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
J & J J&J should only be used in limited situations	(primary) J&J Monovalent: 0.5 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> Pfizer Monovalent: 0.3 mL OR Moderna Monovalent: 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given)	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL

See Child and Adolescent charts for recommendations for those under 18 years of age

Please see CDC Interim Clinical Considerations for official guidance.

www.immunizear.org

COVID-19 Vaccine Recommendations

Healthy Children and Adolescents: Administration of Primary Series and Booster Doses (ages 6 months through 17 years)

Date: October 12, 2022



PRIMARY SERIES (monovalent products only)					BOOSTER DOSES (bivalent products only)	
Row Color = Cap Color	Dose 1		Dose 2		Booster	
Pfizer Cap: Maroon Age: 6 mo – 4 years	(primary) 0.2 mL	Wait 3 – 8 weeks →	(primary) 0.2 mL	Wait 8 weeks →	(primary) 0.2 mL	NOT CURRENTLY RECOMMENDED
Pfizer Cap: Orange Age: 5 – 11 years	(primary) 0.2 mL	Wait 3 – 8 weeks →	(primary) 0.2 mL			Wait 2 months → (Regardless of previous monovalent booster doses given) Pfizer (orange cap) Bivalent: 0.2 mL OR Moderna Bivalent: 0.25 mL *Moderna Bivalent 6 years and older
Pfizer Cap: Gray or Purple Age: 12 – 17 years (same vaccine product for 18 years and older)	(primary) 0.3 mL	Wait 3 – 8 weeks →	(primary) 0.3 mL			Wait 2 months → (Regardless of previous monovalent booster doses given) Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
Row Color = Label Color	Dose 1		Dose 2		Booster	
Moderna Cap: Dark Blue Label: Magenta Age: 6 mo – 5 years	(primary) 0.25 mL	Wait 4 – 8 weeks →	(primary) 0.25 mL			NOT CURRENTLY RECOMMENDED
Moderna Cap: Dark Blue Label: Purple Age: 6 – 11 years	(primary) 0.5 mL	Wait 4 – 8 weeks →	(primary) 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given) Pfizer (orange cap) Bivalent: 0.2 mL OR Moderna Bivalent: 0.25 mL
Moderna Cap: Red Label: Light Blue Age: 12 – 17 years (same vaccine product for 18 years and older)	(primary) 0.5 mL	Wait 4 – 8 weeks →	(primary) 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given) Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	Dose 1		Dose 2		Booster	
Novavax Age: 12 – 17 years (same vaccine product for 18 years and older)	(primary) 0.5 mL	Wait 3 – 8 weeks →	(primary) 0.5 mL			Wait 2 months → (Regardless of previous monovalent booster doses given) Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL

Moderna Purple Label says “Booster Dose Only”. It CANNOT be used for booster doses anymore.

COVID-19 Vaccine Recommendations

Immunocompromised Children and Adolescents: Administration of Primary Series and Booster Doses (ages 6 months through 17 years)

Date: October 12, 2022



PRIMARY SERIES (monovalent products only)						BOOSTER DOSES (bivalent products only)	
Row Color = Cap Color	Dose 1		Dose 2		Dose 3	Booster	
Pfizer Cap: Maroon Age: 6 mo – 4 years	(primary) 0.2 mL	Wait 3 weeks →	(primary) 0.2 mL	Wait 8 weeks →	(primary) 0.2 mL	NOT CURRENTLY RECOMMENDED	
Pfizer Cap: Orange Age: 5 – 11 years	(primary) 0.2 mL	Wait 3 weeks →	(primary) 0.2 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.2 mL	Wait 2 months → <small>(Regardless of previous monovalent booster doses given)</small>	Pfizer (orange cap) Bivalent: 0.2 mL OR Moderna Bivalent: 0.25 mL <small>*Moderna Bivalent 6 years and older</small>
Pfizer Cap: Gray or Purple Age: 12 – 17 years <small>(same vaccine product for 18 years and older)</small>	(primary) 0.3 mL	Wait 3 weeks →	(primary) 0.3 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.3 mL	Wait 2 months → <small>(Regardless of previous monovalent booster doses given)</small>	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
Row Color = Label Color	Dose 1		Dose 2		Dose 3	Booster	
Moderna Cap: Dark Blue Label: Magenta Age: 6 mo – 5 years	(primary) 0.25 mL	Wait 4 weeks →	(primary) 0.25 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.25 mL	NOT CURRENTLY RECOMMENDED	
Moderna Cap: Dark Blue Label: Purple Age: 6 – 11 years	(primary) 0.5 mL	Wait 4 weeks →	(primary) 0.5 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.5 mL	Wait 2 months → <small>(Regardless of previous monovalent booster doses given)</small>	Pfizer (orange cap) Bivalent: 0.2 mL OR Moderna Bivalent: 0.25 mL
Moderna Cap: Red Label: Light Blue Age: 12 – 17 years <small>(same vaccine product for 18 years and older)</small>	(primary) 0.5 mL	Wait 4 weeks →	(primary) 0.5 mL	Wait 4 weeks →	(primary) <i>(additional dose)</i> 0.5 mL	Wait 2 months → <small>(Regardless of previous monovalent booster doses given)</small>	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL
	Dose 1		Dose 2			Booster	
Novavax Age: 12 – 17 years <small>(same vaccine product for 18 years and older)</small>	(primary) 0.5 mL	Wait 3 weeks →	(primary) 0.5 mL			Wait 2 months → <small>(Regardless of previous monovalent booster doses given)</small>	Pfizer Bivalent: 0.3 mL OR Moderna Bivalent: 0.5 mL

Moderna Purple Label says “Booster Dose Only”. It CANNOT be used for booster doses anymore.

Use of the monovalent Novavax booster dose in limited situations

- People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine **and have not received any previous booster dose(s)** may receive a monovalent Novavax booster dose **at least 6 months after completion of the primary series** if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.

COMMON QUESTIONS

QUESTIONS

Can I administer a Novavax booster to a patient who received 2 doses of Pfizer?

- Technically, if the patient is 18 years or older and has not received a booster dose of an mRNA vaccine, they are eligible to receive a booster using Novavax.
- However, Novavax should only be administered as a booster in limited situations.

QUESTIONS

What do we do if we administer a bivalent booster and the patient has not completed a primary series?

- Use this chart in the CDC Interim Clinical Considerations for guidance on any vaccine administration errors with COVID-19 vaccines.
 - <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-d>

<ul style="list-style-type: none">• Bivalent vaccine incorrectly administered for the primary series	<ul style="list-style-type: none">• Bivalent Pfizer-BioNTech vaccine: Do not repeat dose.• Bivalent Moderna vaccine: Repeat 1 monovalent dose immediately (no minimum interval)[§] because administration of the booster dose will result in a lower-than-authorized dose.
--	--

QUESTIONS

If someone decides they want the flu shot before the COVID-19 booster, how long do they need to wait before they can get the COVID-19 booster?

- There is no official recommendation for a waiting period.
- COVID-19 vaccines may be administered without regard to timing of other vaccines.
- In accordance with general best practices, routine administration of all age-appropriate doses of vaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications exist at the time of the healthcare visit.

QUESTIONS

If someone received one dose of Moderna or Pfizer but never received a second dose, can they get the new bivalent booster?

- NO.
- Patients must complete a primary series before they are eligible to receive a bivalent booster dose.

QUESTIONS

If someone received one dose of J&J as a primary series, then Moderna as a booster, can they get the new booster?

- YES.
- If it has been at least 2 months since their last dose of any monovalent COVID-19 vaccine, they are eligible to receive the new booster.

QUESTIONS

How long should someone wait after being sick with COVID-19 to get a COVID-19 vaccine?

- COVID-19 vaccination is recommended for everyone ages 6 months and older, regardless of a history of symptomatic or asymptomatic SARS-CoV-2 infection.
- Growing epidemiologic evidence indicates that vaccination following SARS-CoV-2 infection further increases protection from subsequent infection and hospitalization, including in the setting of increased circulation of more infectious SARS-CoV-2 strains.
- In addition, people who recently had SARS-CoV-2 infection may consider delaying a primary series dose or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

QUESTIONS

Can you administer COVID-19 vaccines with other vaccines?

- YES. COVID-19 vaccines may be administered without regard to timing of other vaccines. In accordance with general best practices, routine administration of all age-appropriate doses of vaccines simultaneously is recommended for children, adolescents, and adults for whom no specific contraindications exist at the time of the healthcare visit.
- Exception: Monkeypox vaccine
 - If monkeypox is received, patients might consider waiting 4 weeks after vaccination to receive a COVID-19 vaccine. This recommendation is due to a slight increased risk of myocarditis/pericarditis.
 - If COVID-19 vaccine is administered first, then a patient is eligible to receive a monkeypox vaccine, the monkeypox vaccine should be given without regards to timing. No minimum interval is necessary.

QUESTIONS

If someone has received either all Pfizer or all Moderna, is there a preference on which new booster product they should receive?

- NO.
- There is no official recommendation or preference for either Pfizer or Moderna.

QUESTIONS

Where can I find this information?

- Great question!
- ALL of the recommendations and guidelines are available on the CDC's website
 - Direct Link: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- Charts with updated guidelines are available on the Immunize Arkansas website.
 - Direct Link: <https://www.immunizear.org/covid-19>

RESOURCES

- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/index.html>